On August 26, 2021, Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine) announced that Dr. Xiaoli Qin was appointed as Chief Scientific Officer (CSO) and promoted to Senior Vice President to lead the research and early development.
Dr. Jinfu Yang, the co-founder and President of Zenshine, said, "As an outstanding research scientist of biology and translational science, Dr. Qin gained decades of experiences in the bio-pharma industry. Dr. Qin will lead the research and development team to speed up our research pipeline and launch more milestone events. We expect that Dr. Qin will burst into bloom in her new role and reshape Zenshine to be a science driven, leading innovative biotech firm with high influences globally."
Zenshine is a clinical stage biopharmaceutical company, focused on small molecule therapeutics in the areas of cancer, viral infection and inflammation. Our mission is to apply the best science to serve patients. Zenshine leverages the team’s extensive expertise and experience in developing proprietary chemical entities with well-defined differentiation to benefit the patients. By targeting key biological pathways to disrupt virus replication, directly block tumor growth and enhance anti-tumor immune responses, Zenshine commits to providing bench-side to bed-side solutions and delivering the best-in-class or first-in-class therapeutics.